Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.
May 24, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals and maintained a $26 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $26 price target by a reputable analyst suggests strong confidence in Phathom Pharmaceuticals' future performance. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100